SPORE in Lung Cancer

肺癌中的孢子

• 批准号: 8664635
• 负责人: PAUL A. BUNN
• 金额: $ 216.2万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-05-20 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8664635
• 关键词: Agonist; Award; Bioinformatics; Biological Markers; Biometry; Cancer Patient; Chemoprevention; Clinical; Clinical Trials; Collaborations; Colorado; Couples Therapy; Data; Detection; Development; Doctor of Philosophy; Early Diagnosis; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor; Fibroblast Growth Factor Receptors; Future; Goals; Grant; Histology; Histone Deacetylase Inhibitor; Holly; Human; Human Resources; Industry; Informatics; Lead; Lung nodule; Malignant Neoplasms; Malignant neoplasm of lung; Modeling; Mutation; Non-Small-Cell Lung Carcinoma; Outcome; Patient Selection; Patient observation; Patients; Peer Review; Peroxisome Proliferator-Activated Receptors; Phase III Clinical Trials; Pilot Projects; Play; Population Sciences; Prevention; Progress Reports; Prostaglandins I; Publishing; Randomized; Reporting; Research; Research Personnel; Resources; Review Literature; Risk; Role; Scientist; Services; Signal Transduction; Survival Rate; System; Testing; Therapeutic; Tissue Banking; Tissue Banks; Tissues; Translational Research; Translations; Tyrosine Kinase Inhibitor; Wolves; anticancer research; base; cancer diagnosis; cancer initiation; cancer therapy; career; career development; design; flexibility; high risk; improved; low-dose spiral CT; mortality; novel; programs; research study; screening; success

DESCRIPTION (provided by applicant): The goal of the Colorado Lung Cancer SPORE program is to conduct translational research studies that will lead to a reduction in the lung cancer mortality rates through improved early detection, prevention, and treatment. This goal is accomplished through four novel projects, a developmental research program, and a career development program all of which are supported by four interacting shared core resources. The future impact of the program will be to hasten translation of scientific discoveries from their development to approved human use of products and services benefiting patients. The projects proposed for this next cycle are Targeting FGFR Signaling in Lung Cancer (Proj. 1); Improving the Outcome of EGFR TKI Therapy Using Rational Combinations (Proj. 2); Prostacyclin and Peroxisome Proliferator-Activated Receptor-y in Lung Cancer (Proj. 3); and Predictors of Pulmonary Nodule Malignancy (Proj. 4). The proposed shared core resources are a Tissue Bank and Biomarkers Core (A); Clinical Trials Core (B); Biostatitistics/Bioinformatics/lnformatics Core (C); and Administrative Core (D). Each Core will facilitate the translation of the research conducted by the Projects. Our SPORE studies have already had a strong impact by contributing to a transformation in the way high risk subjects and lung cancer patients are approached and treated. We are proud of our role in: 1) the development and approval of EGFR TKI therapy coupled with predictive mariners for patient selection; 2) the approval of crizotinib and the use of the FISH break-apart probe as a predictive biomarker; 3) the use of etinostat (HDAC inhibitor) for improving outcome of EGFR TKI therapy; 4) the huge potential of low dose spiral CT screening to reduce lung cancer mortality, especially if barriers can be overcome; 5) changing the landscape of chemoprevention trials allowing rapid completion of moderately sized trials and the potential for a major national randomized phase III trial. We believe that our SPORE studies and collaboration have played a key role in the transformation of lung cancer diagnosis and therapy and that our proposed studies will be equally effective in bringing new products and approaches to lung cancer patients. We believe that we can continue our success in the next grant cycle with translation of discovery to early SPORE trials and handoff of more advanced discoveries to industry and cooperative groups.

描述（由申请人提供）：科罗拉多州肺癌 SPORE 计划的目标是进行转化研究，通过改进早期检测、预防和治疗来降低肺癌死亡率。这一目标是通过四个新颖的​​项目、一个发展研究计划和一个职业发展计划来实现的，所有这些项目都得到四个相互作用的共享核心资源的支持。该计划的未来影响将是加快科学发现从开发到批准人类使用的产品和服务的转化，造福患者。为下一个周期提议的项目是靶向肺癌中的 FGFR 信号传导（项目 1）；使用合理组合改善 EGFR TKI 治疗的结果（项目 2）；肺癌中的前列环素和过氧化物酶体增殖物激活受体-y（项目 3）；和肺结节恶性肿瘤的预测因子（项目 4）。拟议的共享核心资源是组织库和生物标志物核心 (A)；临床试验核心（B）；生物统计/生物信息学/信息学核心（C）；和行政核心（D）。每个核心将促进项目研究成果的转化。我们的 SPORE 研究已经产生了巨大的影响，有助于改变高风险受试者和肺癌患者的接触和治疗方式。我们为自己在以下方面所发挥的作用感到自豪：1) EGFR TKI 疗法的开发和批准以及患者选择的预测性预测； 2) 克唑替尼的批准以及 FISH 分离探针作为预测生物标志物的使用； 3) 使用etinostat（HDAC抑制剂）改善EGFR TKI治疗的结果； 4) 低剂量螺旋CT筛查在降低肺癌死亡率方面具有巨大潜力，特别是如果障碍能够克服的话； 5) 改变化学预防试验的格局，允许快速完成中等规模的试验，并有可能进行主要的国家随机 III 期试验。我们相信，我们的 SPORE 研究和合作在肺癌诊断和治疗的转变中发挥了关键作用，并且我们提出的研究将同样有效地为肺癌患者带来新产品和方法。我们相信，我们可以在下一个资助周期中继续取得成功，将发现转化为早期 SPORE 试验，并将更先进的发现移交给行业和合作团体。